Genmab ADR
Genmab ADR (GMAB) Straddle
GMAB straddle scan found 36 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 45.1%.
Read more
Trading a GMAB straddle lets you take a pure volatility position on Genmab ADR without committing to a direction. Genmab ADR's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate GMAB straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on GMAB profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Genmab ADR stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the GMAB straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies.
The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the GMAB straddle is the cleanest expression of that view. Our scanner prices every GMAB straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a GMAB straddle into a catalyst or short a GMAB straddle to harvest decay, the options straddle setups that matter are all in one place.
| Nov 20, 2026 | 45.00 | $11.30 | 64 | 3% | 45.1% | $56.30 | $33.70 | 0 |
| Jan 19, 2029 | 45.00 | $19.75 | 855 | 3% | 43.9% | $64.75 | $25.25 | 0 |
| Dec 18, 2026 | 45.00 | $12.15 | 92 | 3% | 41.1% | $57.15 | $32.85 | 0 |
| May 21, 2027 | 50.00 | $18.60 | 246 | 3% | 41.0% | $68.60 | $31.40 | 0 |
| Jan 19, 2029 | 40.00 | $17.85 | 855 | 3% | 40.2% | $57.85 | $22.15 | 0 |
| Jan 21, 2028 | 45.00 | $17.60 | 491 | 3% | 39.4% | $62.60 | $27.40 | 0 |
| Jan 15, 2027 | 45.00 | $12.88 | 120 | 3% | 38.9% | $57.88 | $32.13 | 0 |
| Jan 15, 2027 | 25.00 | $11.33 | 120 | 3% | 38.8% | $36.33 | $13.68 | 78 |
| Jan 21, 2028 | 40.00 | $14.85 | 491 | 3% | 37.7% | $54.85 | $25.15 | 0 |
| May 21, 2027 | 45.00 | $14.95 | 246 | 3% | 37.5% | $59.95 | $30.05 | 0 |
As of September 22, 2026
Find the right straddle before volatility moves
Track GMAB straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.
Start your 14-day free trial→